EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges

被引：45

作者：

Janani, Balakarthikeyan ^{[1
]}

Vijayakumar, Mayakrishnan ^{[2
]}

Priya, Kannappan ^{[1
]}

Kim, Jin Hee ^{[2
]}

Prabakaran, D. S. ^{[3
,4
]}

Shahid, Mohammad ^{[5
]}

Al-Ghamdi, Sameer ^{[6
]}

Alsaidan, Mohammed ^{[7
]}

Othman Bahakim, Nasraddin ^{[5
]}

Hassan Abdelzaher, Mohammad ^{[5
,8
]}

Ramesh, Thiyagarajan ^{[5
]}

机构：

[1] Bharathiar Univ, Dept Biochem, PSG Coll Arts & Sci Autonomous, Coimbatore 641014, Tamil Nadu, India

[2] Sejong Univ, Dept Integrat Biosci & Biotechnol, Coll Life Sci, 209 Neugdong Ro, Seoul 05006, South Korea

[3] Chungbuk Natl Univ, Coll Med, Dept Radiat Oncol, Chungdae Ro 1, Cheongju 28644, South Korea

[4] Ayya Nadar Janaki Ammal Coll Autonomous, Dept Biotechnol, Srivilliputhur Main Rd, Sivakasi 626124, Tamil Nadu, India

[5] Prince Sattam Bin Abdulaziz Univ, Coll Med, Dept Basic Med Sci, Al Kharj 11942, Saudi Arabia

[6] Prince Sattam Bin Abdulaziz Univ, Coll Med, Family & Community Med Dept, Al Kharj 11942, Saudi Arabia

[7] Prince Sattam Bin Abdulaziz Univ, Coll Med, Dept Internal Med, Al Kharj 11942, Saudi Arabia

[8] Al Azhar Univ, Dept Med Biochem, Fac Med, Assiut Branch, Assiut 71515, Egypt

来源：

VACCINES | 2022年 / 10卷 / 04期

关键词：

colorectal cancer; EGFR; nanocarriers; nanomedicine; cetuximab; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; CARBON NANOTUBES; COLON-CANCER; CETUXIMAB; NANOPARTICLES; ACTIVATION; CARCINOMA; MICELLES;

D O I：

10.3390/vaccines10040499

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are diagnosed at advanced stages with metastasis-this poses challenges for effective surgical control and future tumor-related mortality. There are numerous diagnostic methods that can be used to reduce the risk of colorectal carcinoma. Among these, targeted nanotherapy aims to eliminate the tumor and any metastasis. Active targeting can increase the effectiveness and quantity of drugs delivered to the target site. Antibodies that target overexpressed receptors on cell surfaces and indicators are coupled with drug-loaded carriers. The major target receptors of chemotherapeutic drugs delivery include VEGFR, EGFR, FGFR, HER2, and TGF. On account of its major and diverse roles in cancer, it is important to target EGFR in particular for better tumor selection, as EGFR is overexpressed in 25 to 82% of colorectal carcinoma cases. The EGFR monoclonal immunoglobulins cetuximab/panitumumab can thus be used to treat colorectal cancer. This review examines carriers that contain cetuximab-conjugated therapeutic drugs as well as their efficacy in anticancer activities.

引用

页数：15